Publications by authors named "Robert Orlowski"

Are you Robert Orlowski?   Register this Author









Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
Mod Pathol 2017 Oct 30;30(10):1378-1386. Epub 2017 Jun 30.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.


The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
Neoplasia 2017 Oct 30;19(10):772-780. Epub 2017 Aug 30.
Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 511436, China. Electronic address:









Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
Eur J Haematol 2016 Oct 15;97(4):342-7. Epub 2016 Feb 15.
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Clin Cancer Res 2016 Oct 13;22(19):4901-4912. Epub 2016 Jun 13.
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.











American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.
J Biol Chem 2015 Dec 19;290(50):29854-68. Epub 2015 Oct 19.
the Departments of Lymphoma and Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030


Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Clin Lymphoma Myeloma Leuk 2015 Nov 5;15(11):687-93. Epub 2015 Aug 5.
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.
Nat Commun 2015 Oct 12;6:8428. Epub 2015 Oct 12.
The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
J Clin Oncol 2015 Sep 3;33(26):2863-9. Epub 2015 Aug 3.
Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome, Rome; Elena Zamagni and Michele Cavo, Istituto di Ematologia Seragnoli, Università di Bologna, Bologna, Italy; Hervé Avet-Loiseau and Michel Attal, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse; Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, Centre Hospitalier Regionale et Universitaire Lille, Lille; Philippe Moreau, University Hospital Hotel-Dieu, Nantes, France; Henk M. Lokhorst, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC, Rotterdam, the Netherlands; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Laura Rosinol, Hospital Clínic, Institut Clínic d'Investigacions Biomèdiques Ausgust Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jésus San Miguel, Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, IDISNA, Pamplona, Spain; Paul Richardson and Kenneth C. Anderson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Shaji Kumar and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA; Robert Z. Orlowski, The University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX; Gareth Morgan, Myeloma Institutes for Research Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Brian G.M. Durie, Cedars-Sinai Comprehensive Canc



Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med 2015 Aug 2;373(7):621-31. Epub 2015 Jun 2.
From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.L.); National and Kapodistrian University of Athens, Athens (M.D.); A.O.U. San Giovanni Battista di Torino-Ospedale Molinette, Turin, Italy (A.P.); QEII Health Science Center and Dalhousie University, Halifax, NS (D.W.), Cross Cancer Institute and University of Alberta, Edmonton (A.B.), and Princess Margaret Cancer Centre, Toronto (D.R.) - all in Canada; Silesian Medical University, Katowice (S.G.), and Medical University of Lublin, Lublin (A.W.-C.) - both in Poland; Charles University Hospital, Prague, Czech Republic (I.S.); University Hospital, Nantes, France (P.M.); Complejo Asistencial Universitario de Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Ramat Aviv - both in Israel (H.M.); Ankara University, Ankara, Turkey (M.B.); Alfred Health-Monash University, Melbourne, VIC, Australia (A. Spencer); Barts and the London NHS Trust, London (H.O.); University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); Kyoto Prefectural University of Medicine, Kyoto (M.T.), and Nishigunma National Hospital, Shibukawa (M.M.) - both in Japan; Universitätsklinikum der Technische Universität, Dresden (C.R.), and Universitätsklinikum Würzburg, Würzburg (H.E.) - both in Germany; Zeikenhuis Netwerk Antwerpen (ZNA) Stuivenberg, Antwerp, Belgium (K.L.W.); AbbVie Biotherapeutics, Redwood City, CA (A. Singhal); Bristol-Myers Squibb, Princeton, NJ (J.K.), Wallingford, CT (E.B.), and Braine-l'Alleud, Belgium (V.P.); and Dana-Farber Cancer Institute, Boston (K.C.A., P.R.).

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Clin Cancer Res 2015 Jun 6;21(11):2538-45. Epub 2015 Mar 6.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.
J Hematol Oncol 2015 Jun 24;8:74. Epub 2015 Jun 24.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.



Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Leuk Res 2015 Mar 3;39(3):371-9. Epub 2015 Jan 3.
Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0853, Houston, TX 77030, USA; The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Houston, TX 77030, USA. Electronic address:

Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Neoplasia 2015 Mar;17(3):289-300
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:




Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Lancet Oncol 2014 Nov 15;15(12):1311-8. Epub 2014 Oct 15.
Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Blood 2014 Oct 10;124(17):2687-97. Epub 2014 Sep 10.
Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA; Virginia Institute of Molecular Medicine, Virginia Commonwealth University, Richmond VA.

Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.
Mol Cell Biol 2014 Sep 7;34(18):3435-49. Epub 2014 Jul 7.
Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia, USA Department of Biochemistry, Virginia Commonwealth University and Massey Cancer Center and Virginia Institute of Molecular Medicine, Richmond, Virginia, USA

Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Clin Cancer Res 2014 Jun 11;20(12):3174-86. Epub 2014 Apr 11.
Authors' Affiliations: Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Heath, Department of Neurosciences, University of Minnesota Twin Cities, Minneapolis, Minnesota; Departments of Pathology, Oncology, and Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland; and Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas


Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
J Hematol Oncol 2014 May 9;7:41. Epub 2014 May 9.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, Texas 77030, USA.

Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
PLoS One 2014 4;9(3):e89064. Epub 2014 Mar 4.
Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, Virginia, United States of America; Department of Biochemistry, Virginia Commonwealth University and the Massey Cancer Center and Institute of Molecular Medicine, Richmond, Virginia, United States of America.

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
PLoS One 2014 2;9(9):e103015. Epub 2014 Sep 2.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.


International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.
Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.





A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
Cancer Epidemiol Biomarkers Prev 2016 12 1;25(12):1609-1618. Epub 2016 Sep 1.
Keck School of Medicine of USC and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med 2016 10;375(14):1319-1331
From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).











OF